Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

F. Cortiula*, D. De Ruysscher, M. Steens, R. Wijsman, A. van der Wekken, M. Alberti, L.E.L. Hendriks

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Adjuvant durvalumab is the standard of care for patients with stage III unresectable non-small cell lung cancer (NSCLC), without progression after concurrent chemo-radiation (CCRT). Patients with stage III NSCLC harbouring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements do not seem to benefit from durvalu-mab. Data are lacking about patients harbouring other driver genomic alterations (dGA). We per-formed a multicentre (N = 4, Netherlands and Italy) retrospective study including consecutive patients with unresectable stage III NSCLC and treated with CCRTdwith or without adjuvant durvalumabdbetween 2016 and 2022. We enrolled 271 patients; 130 of which received adjuvant durvalumab. Sixty-six patients had dGA (41 KRAS mutations, 4 EGFR common mutations and 21 uncommon dGA). In the entire population, the median PFS was 24.9 months (95% CI 17.5e32.4) and 12.6 months (95% CI 9.0e16.1) with and without durvalumab (p = 0.001). In the dGA group (excluding common EGFR), mPFS was 12.3 months (95% CI 7.8-16.8) with and 7.6 (95% CI 3.4-11.9) without durvalumab (p = 0.038). For patients with KRAS mutations, mPFS was 12.3 months (95% CI 3.6-20.9) with and 7.2 months (95% CI 1.8-12.6) without durvalumab (p = 0.12). Among patients with uncommon dGA, mPFS was 12.9 months (95% CI 8.4-17.4) with and 7.6 months (95% CI 1.4-14) without durvalumab (p = 0.23). We have shown a meaningful survival benefit of adjuvant durvalumab in patients har-bouring KRAS mutations and uncommon dGA. This is the largest stage III NSCLC cohort showing the efficacy of durvalumab in patients with uncommon dGA. Further prospective studies are needed to confirm our results.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY -NC-ND license (
Original languageEnglish
Pages (from-to)172-178
Number of pages7
JournalEuropean Journal of Cancer
Issue number1
Publication statusPublished - 1 May 2023


  • Stage III NSCLC
  • Unresectable NSCLC
  • Driver genomic alterations
  • KRAS mutation
  • Uncommon driver genomic alterations
  • Adjuvant immunotherapy
  • Progression-free survival


Dive into the research topics of 'Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations'. Together they form a unique fingerprint.

Cite this